Expose Drug Company Bribes: International Whistleblowers Can Anonymously Expose Drug Company Illegal Bribery Schemes and Collect Large Financial Rewards by International Drug Company Bribe Whistleblower Reward Lawyer Jason S. Coomer
The Foreign Corrupt Practices Act (FCPA) prohibits bribery of foreign officials by U.S. and foreign companies listed on the U.S. securities exchange. Further, bounty actions offer large financial rewards to international whistleblower who anonymously expose significant bribery schemes, frauduelnt seeding trial schemes, and other Foreign Corrupt Practices Act violations. International Drug Company Whistleblowers who properly report violations of the FCPA by a U.S. or foreign company listed on the U.S. securities exchanges can recover a large reward for exposing FCPA violations. These whistleblowers can anonymously expose bribery schemes through a lawyer and protect their identify. If you are aware of a significant Foreign Corrupt Practice Act violation by a drug company and are interested in a confidential review of a whistleblower bounty action, please feel free to contact International Drug Company Bribe Whistleblower Reward Lawyer Jason Coomer via e-mail message or use our submission form.
Drug Company Bribes in China, Brazil, Russia, India, Venezuela, Poland and Ukraine for Procurement Contracts Are Becoming More Common And Can Be The Basis For Large Bounty Action Rewards
Every year over $4.1 trillion (US dollars) is spent worldwide on health services including approximately $850 billion (US dollars) that is spent in the pharmaceutical market on drugs and medications. In 2011, it is estimated that global pharmaceutical sales are expected to grow by 5% to 7% to around $880 billion. This growth in sales is led by the 17 so-called "pharmerging countries," which include China, Brazil, Russia, India, Venezuela, Poland, and Ukraine. These "pharmerging countries", are forecast to see their pharmaceutical spending grow at a 15% to 17% rate in 2011, to between $170 billion and $180 billion overall.
Drug Companies Commonly Target Pharmering Countries with Bribery Schemes including Illegal Seeding Trials and Switch Campaigns That Violate the Foreign Corrupt Practices Act
Eight pharmerging countries are amongst the top 20 world pharmaceutical markets, and China is one of the “top three” or will be in the near future. A few high-profile pharmaceutical companies have been successful in gaining a foothold in these pharmering countries. These footholds include Abbott’s acquisition of Piramal Healthcare in India — a deal that could potentially make the US giant the top player in this country. Bayer's and Novartis' investments in China including Novartis' commitment to invest $1 billion USD in R&D in China and its $125 million USD investment to buy 85 percent stake in a privately held vaccine company. Pfizer has made inroads into the Russian health care system with a discount-card system in Russia Sanofi Aventis has purchased Medley, Brazil’s third-largest pharmaceutical company. GSK and Lilly have also announced anticipated doubling their revenue in emerging markets by 2015.
It is estimated that approximately 10 to 25% of public health care procurement spending including drug contracts, medicine purchases, and pharmaceutical contracts are lost to corrupt and fraudulent acts. As such, there is an international movement to reward pharmaceutical professionals and health care professionals that expose fraudulent and corrupt practices that cost hundreds of billions of dollars and cost lives. This international movement includes SEC Foreign Corrupt Practices Act Whistleblower Reward Lawsuits and traditional Qui Tam False Claims Act Whistleblower Reward Lawsuits.
Drug Companies That Violate The Foreign Corrupt Practices Act Are The Target of SEC Whistleblower Reward Bounty Actions
Under the Foreign Corrupt Practices Act and the new SEC Whistleblower Incentive Program, whistleblowers with original and specialized knowledge and evidence of corporate bribery and illegal kickbacks are eligible to recover large economic awards. By gathering this evidence and going through a lawyer, these whistleblowers can protect their identity through the process and potentially collect large rewards of 10% to 30% of the monetary sanctions including disgorged funds. If you are aware of an illegal bribe or illegal kickback that was used to secure a large contract,please feel free to contact International Whistleblower Lawyer Jason Coomer via e-mail message or use our submission form about a potential SEC Whistleblower Incentive Program Action or other Whistleblower Bounty Action.
Foreign Corrupt Practices Act Whistleblower Laws Apply to All Foreign and U.S. Companies Listed on the U.S. Securities Exchanges as well as their Subsidiaries, Joint Venture Partners, and Agents
The Foreign Corrupt Practices Act (FCPA) applies to “issuers” (U.S. and foreign companies listed on U.S. securities exchanges and their employees); “domestic concerns,” which run the gamut of business entities organized under U.S. laws or with their principal place of business in the United States; the officers, directors, employees, and agents of those U.S. business entities (irrespective of nationality); U.S. citizens; U.S. resident aliens; “any person,” including all foreign persons, who commit an act in furtherance of a foreign bribe while in the United States, and U.S. businesses and nationals acting abroad. A Company must require all of its affiliated companies and all of their employees to comply with the Foreign Corrupt Practices Act.
The SEC Targets Illegal Bribery Schemes and Other Violations of the Foreign Corrupt Practices Act
Corporations that pay illegal kickbacks and bribes to government officials and former government officials in exchange for contracts including large building projects can be brought to justice and made to pay large penalties under the Foreign Corrupt Practices Act and whistleblowers that bring these corporations to justice may be able to collect large economic rewards under the Securities Exchange Act (SEC Whistleblower Bounty Actions) and the Commodity Exchange Act (CFTC Whisteblower Bounty Actions).
Anonymous Illegal Drug Company Bribe Bounty Actions Can Pay Large Financial Rewards Including a Percentage of the Benefit of the Bribe
The Illegal Bribe Whistleblower or Illegal Kickback Whistleblower may be entitled to not only the amount of the illegal bribe or kickback, but the benefit of the illegal bribe or kickback. In cases where $100,000.00 bribe is made to obtain a $100 million building project, the Illegal Bribe Whistleblower or Illegal Kickback Whistleblower may be entitled to 10 to 30% of the $100,000,000.00 and the $100,000.00 translating into a $10 million to $30 million award.
Foreign Corrupt Practices Act Lawyer Jason S. Coomer
As an International Whistleblower Foreign Corrupt Practices Act Lawyer and SEC International Business Whistleblower Reward Lawyer, Jason S. Coomer commonly works with solicitors, barristers, attorneys, attourneys, advokats, and abogados around the world to expose corruption and collect rewards for their clients. These clients include international professionals including medical doctors, compliance officers, pharmaceutical representatives, pharmaceutical executives, drug company marketing experts, and lawyers.
If you are the original source with special knowledge of fraud and are interested in learning more about a potential lawsuit please feel free to contact Lawyer Jason Coomer via e-mail message or use our submission form